Is there a patent that covers “regorafenib synthesis” using an isocyanate/aniline/urea route?
I can’t determine a specific “regorafenib synthesis” patent from the information provided. The phrase “isocyanate aniline urea” sounds like a generic chemical transformation (forming a urea linkage from an amine and an isocyanate), and those building blocks can appear in multiple independent patent families for different kinase inhibitors or intermediate chemistry. To identify the right patent(s), you’d typically need at least one of the following: a patent number, assignee (company), publication year, or an intermediate name/cas number.
If you share any of the following, I can help pinpoint what patents likely match: the patent publication number (WO/EP/US), the company name (e.g., Bayer or other applicants), or the exact reaction/intermediate wording you’re seeing (including compound names).
How does the isocyanate + aniline → urea step relate to regorafenib synthesis?
Mechanistically, an aniline (an aromatic amine) can react with an isocyanate to form a urea (Ar-NH-CO-NH-). In medicinal chemistry, ureas are common “linker” motifs used to connect heterocycles and aryl groups. In patent literature, this kind of step often appears when a patent describes preparation of a specific urea-containing intermediate that later couples to the rest of the regorafenib scaffold.
However, regorafenib’s specific synthetic scheme depends on exactly where the urea sits in the final molecule and which protected/unprotected functional groups are present at that stage—so “isocyanate aniline urea” by itself is not enough to confirm it matches regorafenib specifically.
What to search in patents if you’re looking for this chemistry
If your goal is to find the regorafenib synthesis patent(s) that mention an “isocyanate + aniline → urea” step, useful search terms typically include:
- “regorafenib” plus “urea” or “isocyanate”
- “aniline” or “aryl amine” plus “isocyanate”
- intermediate names (often the urea-containing intermediate is named in the patent)
- assignee names tied to regorafenib development
If you paste the exact intermediate or fragment name from the document you’re reading, I can suggest more targeted query terms (and what to look for in the claims vs examples).
Are you asking about infringement or patent validity tied to manufacturing steps?
Those are different questions than simply identifying patents that disclose regorafenib synthesis. If you’re asking about whether using an isocyanate/aniline urea route infringes a particular patent, you’d need:
- the specific patent claims (not just the examples)
- the scope of the claimed intermediate(s) and process steps
- whether the urea-forming step is actually claimed (e.g., in a “process for preparing intermediate X” claim) versus only described in embodiments
Without the specific patent publication, it’s not possible to assess infringement risk.
---
Quick clarification
To answer your question accurately, which one do you mean?
1) Find the specific patent publication that mentions regorafenib synthesis with an isocyanate/aniline urea step, or
2) Determine whether a particular synthesis route infringes or avoids a specific regorafenib patent?
If you share the patent number (or the assignee and approximate year) or the exact intermediate name from your document, I can narrow it down.